行情

AXSM

AXSM

Axsome
NASDAQ

实时行情|Nasdaq Last Sale

30.43
+2.96
+10.78%
已收盘, 19:53 11/19 EST
开盘
27.77
昨收
27.47
最高
30.55
最低
27.73
成交量
181.20万
成交额
--
52周最高
30.55
52周最低
1.940
市值
10.50亿
市盈率(TTM)
-18.9536
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AXSM 新闻

  • 沪指低开低走 纽约联储主席称美经济面临下行风险
  • 新浪财经.1小时前
  • 击败亚马逊微软 谷歌赢得沃达丰数据服务大单
  • TechWeb.5小时前
  • 道明证券:"巨大风险事件"使风险对冲成2020年的佳选
  • 新浪财经综合.5小时前
  • 港交所:推出阿里巴巴集团控股有限公司股票期权
  • 新浪科技.6小时前

更多

所属板块

生物技术和医学研究
+2.16%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

AXSM 简况

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
展开

Webull提供Axsome Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。